Immix Biopharma, Inc.
IMMX
$2.00
-$0.12-5.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.79% | 5.60% | 32.69% | -62.75% | 16.47% |
| Total Depreciation and Amortization | 34.80% | 43.34% | 59.46% | 6.58% | 1.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.71% | 23.06% | -3.83% | 17.43% | -28.27% |
| Change in Net Operating Assets | -63.69% | -25.46% | 10.00% | 255.63% | -381.57% |
| Cash from Operations | -215.10% | -14.15% | 63.43% | 23.21% | -37.35% |
| Capital Expenditure | -88.48% | 86.65% | -86.81% | -179.61% | 67.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -88.48% | 86.65% | -86.81% | -179.61% | 67.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | 651.25% | 68.13% | -209.13% | 158.43% | 185.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.24% | 12.33% | 53.12% | 19.82% | -145.25% |